ANTI-RAGE TARGETS IN CACHEXIA: HMGB1, S100B, S100A1

Abstract

Cachexia mediated by the multiligand receptor RAGE (receptor for advanced glycation end products) and its ligands HMGB1, S100B, and S100A1 is a formidable multifactorial complication of the severe course of a number of somatic and malignant diseases. One of the most visualized symptoms of cachexia is a significant decrease in body weight, but the main one is the systemic shutdown of a number of regulatory centers that control the maintenance of homeostasis. Activation of these markers contributes to the launch and intensification of the destructive processes of cachexia, and blocking, in some cases, can reduce their intensity. Among known drugs from various therapeutic groups, there are blockers of one or more markers. For example, papaverine antispasmodic as well as the nootropic anxiolytic tenotene, antibacterial pentamidine and antidepressant duloxetine. The review describes in detail the significance of the listed markers in the pathogenesis of cachexia, especially in malignant pathology. An assumption was made about the possible control of cachectic progression with the help of such blockers to improve quality of the life patients.The Internet resource PubMed and the ELIBRARY database were used as primary sources. Access to the full text of the articles is carried out on the websites of the publishing houses Springer and Elsever.